Sirolimus Rx injection sites: where and how it's given

Last updated 2026-07-27

Is sirolimus given as an injection or a pill?

Sirolimus, sold under the brand name Rapamune, is FDA-approved as an oral tablet and an oral solution. That's it. There is no FDA-approved injectable sirolimus product for the transplant indication, and there is no approved injection site because there is no approved injection ^[1]. The FDA label for Rapamune describes it plainly: "RAPAMUNE is available as a solution for oral administration containing 1 mg/mL sirolimus" and as tablets in 0.5 mg, 1 mg, and 2 mg strengths ^[1]. Patients take it by mouth, once daily, consistently either with or without food, and blood levels get monitored with trough labs in the transplant setting. So if you searched "sirolimus injection sites" expecting a diagram of deltoid versus thigh versus abdomen the way you'd see for insulin or testosterone, that diagram doesn't exist for FDA-labeled sirolimus. The confusion is understandable because a lot of longevity-adjacent compounds (peptides, hormones) are subcutaneous injections, and people sometimes assume rapamycin works the same way. It doesn't. For actual dosing mechanics, see Sirolimus Rx dosage and the Sirolimus Rx dosage calculator.

Why do people search for sirolimus injection sites at all?

Three real sources of confusion feed this search, and it's worth untangling each one. First, temsirolimus (Torisel) is a genuinely injectable mTOR inhibitor, a prodrug that converts to sirolimus in the body. It's FDA-approved for advanced renal cell carcinoma and given as a weekly IV infusion over 30 to 60 minutes, through a peripheral line or central line, not a self-administered subcutaneous shot ^[2]. If you saw "mTOR inhibitor" and "injection" together somewhere, this is probably the drug being described. Temsirolimus is not sirolimus, though it shares the same molecular target and converts to sirolimus in the bloodstream. Second, Fyarro (sirolimus protein-bound particles, albumin-bound) is an IV infusion form of sirolimus itself, approved in November 2021 for a rare cancer called malignant perivascular epithelioid cell tumor (PEComa) ^[3]. This is a legitimate injectable sirolimus product, but it's a cancer chemotherapy given by infusion in a clinical setting, nothing like a home injection protocol, and it has zero relevance to longevity dosing. Third, some people conflate "reconstitution" (mixing a compounded oral suspension or powder with a liquid) with "injection prep," because the vocabulary and vials look similar to injectable peptide kits. If you're working with a compounded oral sirolimus product, the correct comparison is how to reconstitute Sirolimus Rx, not an injection guide.

What is temsirolimus and how is it actually injected?

Temsirolimus is given as a weekly intravenous infusion, always by a healthcare professional in an infusion center or clinic, never as a self-administered shot. The FDA label specifies dilution in 0.9% Sodium Chloride Injection and infusion over 30 to 60 minutes, with premedication (usually an IV antihistamine) roughly 30 minutes before each dose to reduce infusion reactions ^[2]. There's no "injection site" in the subcutaneous sense (no rotating between abdomen and thigh) because it's a peripheral or central IV line, the same infrastructure used for other IV chemotherapy. The approved dose is 25 mg infused once weekly for renal cell carcinoma ^[2]. This bears no resemblance to longevity dosing protocols, which use oral sirolimus at 1 to 15 mg roughly once weekly, not IV temsirolimus at cancer-treatment doses. If your interest is longevity and healthspan rather than oncology, temsirolimus isn't the relevant drug at all. It's mentioned here only because it's the actual injectable mTOR inhibitor that searches for "sirolimus injection" are often trying to find.

How is oral sirolimus actually dosed for longevity protocols?

Off-label longevity protocols use oral sirolimus, typically once weekly rather than daily, at doses far lower than transplant regimens. Published human pharmacokinetic and safety work from the PEARL trial (Kaeberlein and colleagues, 2024) tested doses up to roughly 8 mg weekly in an at-home, non-clinical-trial-site cohort and reported general tolerability at that cadence, though this was a safety and biomarker study, not a lifespan trial ^[4]. There is no completed human lifespan trial for rapamycin. This is the single most important fact in the entire sirolimus-for-longevity conversation, and it applies here too: no injection protocol changes that gap. The strong evidence for lifespan extension comes from mice, principally the National Institute on Aging's Interventions Testing Program, which found rapamycin extended median lifespan in genetically heterogeneous mice by roughly 9 to 26% depending on sex, dose, and start age across multiple cohorts ^[5]. That's a real, repeated, peer-reviewed animal result. It is not proof of a human lifespan benefit, injected or oral. For the actual weekly or intermittent schedules people use, see Sirolimus Rx cycle length, and for why the dosing interval matters pharmacologically, see Sirolimus Rx half life. Sirolimus has a long elimination half-life, roughly 57 to 63 hours in stable renal transplant patients per the FDA label, which is exactly why weekly rather than daily dosing is pharmacologically plausible for the off-label longevity use case ^[1].

What does the reconstitution and administration process actually look like?

Compounded oral sirolimus, when prescribed off-label through a telehealth or specialty pharmacy pathway, typically arrives as tablets or a compounded liquid, not as a vial requiring injection technique. Reconstitution, if required, means mixing a powder or concentrate into a measured liquid volume for oral dosing, following the specific pharmacy's instructions exactly, since concentration and diluent vary by compounder. There's no needle, no injection site rotation, no subcutaneous or intramuscular technique to learn. If a compounding pharmacy or prescriber ever hands you something described as injectable sirolimus for a longevity indication, that should raise a real red flag, because no such approved product or established off-label protocol exists for healthy adults. The two legitimate injectable sirolimus-family products (temsirolimus, Fyarro) are both cancer drugs given under direct clinical supervision, not home-administered longevity interventions. Step-by-step mixing guidance, when it's genuinely a liquid formulation, lives at how to reconstitute Sirolimus Rx; actual oral administration guidance is at Sirolimus Rx how to inject, which despite the URL name covers the correct oral administration steps clinicians and compounders actually use for this drug.

What are the real risks people should weigh before considering any mTOR inhibitor protocol?

Immunosuppression is the core, mechanism-based risk, not a side effect footnote. Sirolimus is FDA-approved specifically because it suppresses the immune response to prevent organ transplant rejection, and the label carries a boxed warning about increased susceptibility to infection and the possible development of lymphoma with chronic, higher-dose immunosuppressive use in transplant patients ^[1]. Lower, intermittent off-label doses are pharmacologically intended to reduce this risk relative to daily transplant dosing, but no large controlled human trial has quantified infection risk at those specific off-label doses over years of use. Mouth ulcers (stomatitis) are one of the most commonly reported side effects in the sirolimus label, occurring in roughly a quarter or more of transplant patients on standard daily dosing, and they're frequently reported anecdotally by people using lower weekly doses too ^[1]. Metabolic effects are documented in the label as well: sirolimus is associated with elevated cholesterol and triglycerides (hyperlipidemia) in a substantial proportion of transplant patients, alongside impaired wound healing and, in some patients, new-onset or worsened glucose intolerance ^[1]. Anyone considering an off-label protocol should get baseline and follow-up lipid panels and fasting glucose, regardless of dosing route or schedule. None of these risks are injection-related, because there's no injection. They're pharmacologic, tied to what the drug does to mTOR signaling and immune function, and they apply whether the drug reaches your bloodstream by tablet, oral solution, or (in the cancer setting) IV infusion.

What does the mouse lifespan data actually show, and why doesn't it settle the human question?

The NIA Interventions Testing Program has run rapamycin trials in genetically heterogeneous mice across multiple independent cohorts since roughly 2006, testing different doses, start ages, and sexes. Results have consistently shown lifespan extension, with median lifespan increases commonly cited in the range of 9% to 26% depending on the specific cohort, dose, and sex, and effects appearing even when treatment starts relatively late in life ^[5]. This is genuinely strong, repeated, peer-reviewed animal evidence, run by an NIH-funded program specifically designed to test reproducibility across three independent labs, which is more rigor than most single-lab mouse aging studies get. It's a big part of why rapamycin is the most-discussed candidate longevity drug in serious scientific circles. But mice are not small humans. No completed randomized controlled trial has measured whether any dose or schedule of rapamycin extends human lifespan or healthspan, and the PEARL trial and similar human studies to date have measured safety, tolerability, and biomarkers (like inflammatory markers or self-reported symptoms), not mortality or diagnosed age-related disease incidence over years ^[4]. Anyone telling you rapamycin is "proven" to extend human life is overstating the evidence. Anyone telling you the mouse data is meaningless is underselling genuinely good animal pharmacology. The honest position sits in between, and it applies identically to pills or, mistakenly, injections.

Table: sirolimus-family drugs and how each is actually given

Is there a topical sirolimus, and how does that get applied?

Yes. Hyftor (sirolimus topical gel) is FDA-approved for facial angiofibromas associated with tuberous sclerosis complex in patients 6 years and older, applied directly to the skin lesions, not injected and not swallowed ^[6]. This is a niche dermatologic indication, unrelated to longevity dosing, but it rounds out the full picture of how the sirolimus molecule is actually delivered across all its approved uses: swallowed, infused, or rubbed on skin. Worth restating since it comes up constantly in longevity forums: sirolimus and rapamycin are the same molecule. Rapamycin is the generic scientific name (originally isolated from Streptomyces hygroscopicus soil bacteria on Easter Island, called Rapa Nui, which is where the name comes from); sirolimus is the pharmaceutical name used on FDA labels and prescriptions. Same drug, same mechanism, same lack of an approved injectable route for anything other than the cancer indications covered above.

What should someone actually do if they're considering off-label sirolimus for longevity?

Work with a prescriber who orders baseline labs (lipid panel, fasting glucose or HbA1c, complete blood count, kidney function) before starting, and repeats them periodically. This isn't optional caution, it's the same monitoring framework the FDA label recommends for transplant patients, scaled to a lower-risk but not zero-risk off-label context ^[1]. Understand the route is oral, so there's no injection site rotation, no needle disposal, none of the logistics that come with subcutaneous peptide protocols. What you're managing instead is timing consistency (same day each week is common in published protocols), interaction checks (sirolimus interacts with grapefruit juice, CYP3A4 inhibitors and inducers, and other immunosuppressants), and side effect tracking, especially mouth ulcers and lipid changes ^[1][4]. Get the dose right for your body weight and goals rather than copying a number from a forum post; see the Sirolimus Rx dosage calculator for a starting framework, and read Sirolimus Rx dosage for the reasoning behind common weekly ranges. Sirolimus Rx works with a provider-reviewed pathway and names its fulfilling pharmacy partner directly, rather than shipping product with no clinical oversight attached, which matters more for a drug with real immunosuppressive risk than it would for a supplement.

Frequently asked questions

Is sirolimus given as a shot or a pill?

A pill, or an oral liquid solution. FDA-approved sirolimus (Rapamune) comes as tablets (0.5 mg, 1 mg, 2 mg) or an oral solution, taken by mouth once daily in the approved transplant indication, per the FDA label. There's no approved injectable sirolimus product for that use, so there's no standard injection site to describe.

What is the difference between sirolimus and temsirolimus?

Temsirolimus is a prodrug that the body converts into sirolimus; it's given as a weekly IV infusion for advanced renal cell carcinoma, always in a clinical setting. Sirolimus itself is the oral tablet or solution used for transplant rejection prevention and, off-label, for longevity protocols. They share a mechanism but different routes, doses, and approved uses.

Does Fyarro mean there's now an injectable sirolimus for longevity use?

No. Fyarro is albumin-bound sirolimus given by IV infusion, FDA-approved in November 2021 specifically for a rare tumor called malignant PEComa. It's cancer chemotherapy administered in a clinical setting, not a self-injection product, and it has no established role or safety data for longevity dosing in healthy adults.

Why do longevity protocols use weekly dosing instead of daily?

Sirolimus has a long elimination half-life, roughly 57 to 63 hours according to the FDA label for stable transplant patients, which makes intermittent (often weekly) dosing pharmacologically plausible for reducing continuous immunosuppression while still hitting mTOR intermittently. The PEARL trial tested doses up to about 8 mg weekly in this framework, though it measured safety and biomarkers, not lifespan.

Has rapamycin actually been proven to extend human lifespan?

No. There is no completed human lifespan trial for rapamycin. The strong lifespan-extension data comes from mice, principally the NIA Interventions Testing Program, showing roughly 9 to 26% median lifespan increases across cohorts. Human studies so far, like PEARL, have measured safety and biomarkers over months, not survival over years.

What are the most common side effects people should watch for?

Mouth ulcers (stomatitis), elevated cholesterol and triglycerides, and increased infection susceptibility due to immunosuppression are all documented in the FDA sirolimus label. Impaired wound healing and glucose intolerance are also reported. These risks apply regardless of dosing schedule, and they're the reason baseline and follow-up labs matter for anyone using it off-label.

Can I get sirolimus as a compounded injectable for anti-aging use?

You shouldn't, and legitimate providers won't offer it that way. No approved or established off-label injectable sirolimus protocol exists for longevity use in healthy adults; the only injectable sirolimus-family drugs (temsirolimus, Fyarro) are cancer therapies given under direct clinical supervision at cancer-treatment doses, not home longevity protocols.

What is Hyftor and is it injected?

Hyftor is a topical sirolimus gel, FDA-approved for facial angiofibromas in tuberous sclerosis complex patients age 6 and up. It's applied directly to the skin, not injected and not swallowed. It's a separate, niche approved use of the sirolimus molecule with no relevance to longevity dosing.

Are sirolimus and rapamycin the same drug?

Yes. Rapamycin is the original scientific name for the compound, isolated from a soil bacterium found on Easter Island (Rapa Nui). Sirolimus is the pharmaceutical name used on FDA drug labels and prescriptions. They refer to the identical molecule with the identical mechanism of action (mTOR inhibition).

Does reconstituting compounded sirolimus mean I'll be injecting it?

Not necessarily, and usually not. Reconstitution just means mixing a powder or concentrate with a liquid diluent to prepare an oral dose at the correct concentration, following your specific compounding pharmacy's instructions. It looks similar to injectable peptide prep visually, but the resulting product for sirolimus is taken by mouth.

What labs should I get before starting an off-label sirolimus protocol?

A fasting lipid panel, fasting glucose or HbA1c, complete blood count, and kidney function tests are reasonable baseline labs, mirroring the monitoring framework used in the FDA transplant label, scaled to an off-label lower-dose context. Repeat testing periodically once on the drug helps catch hyperlipidemia or other metabolic shifts early.

Why does sirolimus have a boxed warning?

The FDA label carries a boxed warning about increased risk of infection and lymphoma associated with immunosuppression, particularly relevant at the daily, higher doses used in organ transplant patients to prevent rejection. This reflects the drug's core mechanism, immune suppression, which is the same mechanism people are trying to dose around at lower, intermittent off-label levels.

Sources

1. FDA, Rapamune (sirolimus) prescribing information label, NDA 021083: Sirolimus is FDA-approved as an oral tablet/solution, its half-life, boxed warning, and common side effects like stomatitis and hyperlipidemia
2. FDA, Torisel (temsirolimus) prescribing information, NDA 022088: Temsirolimus is given as a weekly IV infusion at 25 mg for renal cell carcinoma, with premedication
3. FDA, Fyarro (sirolimus protein-bound particles) drug approval, NDA 213973: Fyarro is an IV infusion sirolimus product approved in November 2021 for malignant PEComa
4. Kaeberlein et al., PEARL trial, GeroScience 2024, DOI 10.1007/s11357-024-01173-5: Human trial testing weekly oral sirolimus doses up to approximately 8 mg, measuring safety and biomarkers
5. Harrison et al., NIA Interventions Testing Program rapamycin study, Nature 2009, PMID 19587680: Rapamycin extended median lifespan in genetically heterogeneous mice across ITP cohorts
6. FDA, Hyftor (sirolimus topical gel) drug approval, NDA 213478: Hyftor is a topical sirolimus gel approved for facial angiofibromas in tuberous sclerosis complex